Cleerly ISCHEMIA vs Eko Analysis Software
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a detailed, non-invasive assessment of coronary artery disease and vessel-level ischemia likelihood based on CCTA imaging. This tool is ideal for physicians needing to characterize coronary plaque, assess stenosis severity, and estimate fractional flow reserve to guide personalized treatment plans for patients with suspected or known heart disease.
View Cleerly ISCHEMIA →Choose Eko Analysis Software if…
Choose Eko Analysis Software if you need an AI-powered solution for early detection and ongoing monitoring of cardiovascular conditions like heart murmurs and atrial fibrillation during routine clinical exams or telehealth consultations. This tool integrates with digital stethoscopes to provide real-time, AI-assisted insights from auscultation and ECGs, facilitating proactive heart and lung care at the point of care.
View Eko Analysis Software →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | Eko Analysis Software |
|---|---|---|
| Pricing | Unknown | Freemium with subscription for full features |
| Deployment | Web-based solution | Cloud-based |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Analysis SoftwareEko Analysis Software offers a more accessible and intuitive user experience due to its integration with digital stethoscopes and a mobile app, enabling point-of-care use. Its freemium model also lowers the barrier to entry for basic features, making it more immediately usable for a wider range of clinicians.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA provides a deeper, more comprehensive diagnostic assessment by offering non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA scans. This advanced analysis directly informs personalized diagnosis and treatment planning for coronary artery disease, offering more granular clinical insights than Eko's screening capabilities.
Pricing & Value
Eko Analysis SoftwareEko Analysis Software offers a more transparent and accessible pricing model with its freemium option and clear subscription tiers for full features. This allows users to experience basic functionalities before committing to a paid plan, providing better perceived value and a lower barrier to adoption compared to Cleerly's 'contact for details' approach.
Enterprise Readiness
Cleerly ISCHEMIACleerly ISCHEMIA demonstrates stronger enterprise readiness through its deployment model, which includes data transfer via VPN or virtual appliance and direct API integration with radiology reporting systems like PowerScribe. This indicates a design optimized for seamless integration into existing hospital IT infrastructure and specialized imaging workflows.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA exhibits greater innovation by applying AI to CCTA scans for non-invasive fractional flow reserve (FFR) estimation and comprehensive coronary plaque characterization. This represents a more advanced and novel application of AI in cardiology diagnostics, offering insights that traditionally required invasive procedures.
Support & Docs
Eko Analysis SoftwareEko Analysis Software offers more robust and accessible support and documentation, including a comprehensive online Help Center with multi-language user manuals, FAQs, and how-to videos. It also provides multiple direct contact channels like email, phone, and chat with specified availability, surpassing Cleerly's form-based support.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | Eko Analysis Software |
|---|---|---|
| Name | Cleerly ISCHEMIA | Eko Analysis Software |
| Company | Cleerly | Eko Devices |
| Description | Cleerly ISCHEMIA is an FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Eko Analysis Software is an FDA-cleared AI-powered tool that integrates with Eko's digital stethoscopes and mobile app to assist clinicians in the early detection of cardiovascular diseases like heart murmurs and atrial fibrillation. |
| Primary Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI, Wearables & Remote Monitoring (RPM) |
| Key Features (Selection) | AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination | FDA-cleared AI for heart murmur detection, FDA-cleared AI for atrial fibrillation (AFib) detection, Detection of normal sinus rhythm |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and Eko Analysis Software.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or Eko Analysis Software
Backers
Who funded each tool's parent company.